Method for Analysis of Nanoparticle Hemolytic Properties In Vitro
By M. Dobrovolskaia, J. Clogston, B. Neun, Jennifer B Hall, A. Patri, S. McNeil. Nano letters (Print), 2008
667 citations recorded by the source corpus.
Hemolysis (destruction of red blood cells) in vivo can lead to anemia, jaundice and other pathological conditions, therefore the hemolytic potential of all intravenously administered pharmaceuticals must be evaluated. Nanotechnology-derived devices and drug carriers are emerging as alternatives to conventional small-molecule drugs, and in vitro evaluation of their biocompatibility with blood components is a necessary part of early preclinical development. The small size and unique physicochemical properties of nanoparticles may cause their interactions with erythrocytes to differ from those observed for conventional pharmaceuticals, and may also cause interference with standardized in vitro tests. Separating true hemolytic responses from the false-positive or false-negative results caused by particle interference is important for correct interpretation of these tests. Here we describe validation of an in vitro assay for the analysis of nanoparticle hemolytic properties, and discuss observed nano-interferences with the assay. We propose alternative methods to avoid misleading results from nanoparticles, and discuss the potential relevance of nanoparticle in vitro hemolytic properties to in vivo systems.
Subfields: Biomaterials, Immunology, Physiology
View Paper: https://www.semanticscholar.org/paper/0b89d748fa5251b95ac9c95c788f550e7a74c618
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Avci-Adali
- S. Golombek
- Marbod Weber
- H. Wendel
- L. Hann
- H. Steinle
- C. Schlensak
Citations in the corpus
- Blood-Contacting Biomaterials: In Vitro Evaluation of the Hemocompatibility (2018, background): “C5a stimulates endothelial cells to increasingly express cytokines, chemokines and cell adhesion molecules, such as E-selectin (Newton and Dixit, 2012).”
- Ultrasmall copper-based nanoparticles for reactive oxygen species scavenging and alleviation of inflammation related diseases (2020, neutral): “Additionally, hemolysis rate of nanomaterials must be less than 5% to ensure safety during intravenous administration 48,49 .”